Alliancebernstein L.P. decreased its stake in shares of OraSure Technologies (NASDAQ:OSUR) by 5.8% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 142,736 shares of the medical instruments supplier’s stock after selling 8,820 shares during the quarter. Alliancebernstein L.P. owned about 0.24% of OraSure Technologies worth $2,692,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds also recently made changes to their positions in the company. Oppenheimer Asset Management Inc. acquired a new stake in shares of OraSure Technologies during the 3rd quarter worth approximately $186,000. Shikiar Asset Management Inc. acquired a new stake in shares of OraSure Technologies during the 4th quarter worth approximately $207,000. Quadrant Private Wealth Management LLC acquired a new stake in shares of OraSure Technologies during the 4th quarter worth approximately $300,000. Belpointe Asset Management LLC acquired a new stake in shares of OraSure Technologies during the 3rd quarter worth approximately $315,000. Finally, Sei Investments Co. grew its position in shares of OraSure Technologies by 422.4% during the 3rd quarter. Sei Investments Co. now owns 14,925 shares of the medical instruments supplier’s stock worth $336,000 after buying an additional 12,068 shares during the period. 93.67% of the stock is owned by institutional investors.
NASDAQ OSUR opened at $16.72 on Friday. OraSure Technologies has a 12-month low of $12.02 and a 12-month high of $23.01. The firm has a market capitalization of $1,042.32, a P/E ratio of 32.78, a price-to-earnings-growth ratio of 5.02 and a beta of 1.65.
OSUR has been the subject of several recent analyst reports. BidaskClub downgraded shares of OraSure Technologies from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, March 28th. ValuEngine raised shares of OraSure Technologies from a “hold” rating to a “buy” rating in a research report on Friday, March 2nd. Zacks Investment Research raised shares of OraSure Technologies from a “hold” rating to a “buy” rating and set a $23.00 price target for the company in a research report on Friday, February 9th. Finally, Canaccord Genuity reissued a “buy” rating and issued a $24.00 price target on shares of OraSure Technologies in a research report on Friday, February 2nd. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. OraSure Technologies currently has an average rating of “Buy” and an average target price of $22.25.
In other OraSure Technologies news, Director Stephen S. Phd Tang sold 23,333 shares of OraSure Technologies stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $17.97, for a total transaction of $419,294.01. Following the transaction, the director now directly owns 59,749 shares of the company’s stock, valued at approximately $1,073,689.53. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Brian Smith sold 20,000 shares of OraSure Technologies stock in a transaction on Friday, February 16th. The stock was sold at an average price of $17.97, for a total transaction of $359,400.00. Following the transaction, the executive vice president now directly owns 28,075 shares in the company, valued at $504,507.75. The disclosure for this sale can be found here. Company insiders own 6.40% of the company’s stock.
WARNING: This piece was posted by Ticker Report and is the property of of Ticker Report. If you are viewing this piece on another site, it was copied illegally and republished in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3337122/orasure-technologies-osur-stake-lowered-by-alliancebernstein-l-p.html.
OraSure Technologies Profile
OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.
Want to see what other hedge funds are holding OSUR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OraSure Technologies (NASDAQ:OSUR).
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.